TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $8.26 million during the quarter, compared to analysts’ expectations of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI opened at $5.22 on Friday. The company has a market capitalization of $159.17 million, a PE ratio of -2.10 and a beta of 0.48. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42. The stock’s 50 day moving average price is $5.44 and its 200 day moving average price is $4.75.

Wall Street Analyst Weigh In

TLSI has been the topic of a number of research reports. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price for the company. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Roth Mkm reaffirmed a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $11.56.

Insider Activity at TriSalus Life Sciences

In other news, CFO James Emmett Young purchased 24,000 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average price of $5.40 per share, for a total transaction of $129,600.00. Following the acquisition, the chief financial officer now directly owns 24,000 shares in the company, valued at approximately $129,600. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean Murphy acquired 15,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The shares were purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares of the company’s stock, valued at $970,306.92. The trade was a 8.94 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 54,856 shares of company stock worth $294,608 over the last three months. 32.80% of the stock is currently owned by corporate insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.